CELLECTIS - ADR

CLLSNASDAQ

🏆 #3882 by market capEarnings Nov 13US Equity

$419.87▲ $11.00 (+2.62%)

Simulated price

🔔

Track CLLS

Get earnings, price moves & breaking news on Telegram

Track

24h▲ 2.6%

7d—

14d—

30d—

ytd—

1y—

🏦Market Cap

$149M

Small Cap

📈Revenue Growth (YoY)

+75.8%

High Growth

📊Gross Margin

74.7%

High

💵FCF Margin

-77.5%

Thin

⚖️P/S Ratio

1.9x

Cheap

Otter Score

Weak

No chart data available for CLLS.

Trading Snapshot

Day Range: $418.18 – $424.48
52-Week Range: $1.25 – $5.48
Volume: $3.43B
Avg Volume: $4.48B
Shares Outstanding: 100.4M
Next Earnings: Oct 20, 2026

Fundamentals Snapshot

Annual Revenue: $73M
Last Q Revenue: $5M
P/E Ratio: -2.2
P/S Ratio: 1.9x
EPS (TTM): $-0.65
Dividend Yield: 0.00%
Dilution (1yr): +0.2%

Why Investors Own CLLS

✓High-growth profile — revenue up -0.8% YoY with expanding US Equity exposure.
✓Healthy economics — 44% gross margin and 14% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

CELLECTIS - ADR

CLLS

Financial Trends

Revenue

$73M▲ +75.8% YoY

Gross Margin

86.6%▲ +11.2% YoY

Operating Income

−$33M▼ −44.5% YoY

Free Cash Flow

−$43M▼ −317.7% YoY

Shares Outstanding

100.3M▲ +0.2% YoY

Net Cash

−$56M▼ −$108M YoY

StockOtter · stockotter.space

About CELLECTIS - ADR

Cellectis S.A. is a biotechnology firm in the clinical development stage, concentrating on the creation of immuno-oncology therapies. These therapies harness gene-edited T-cells engineered to express chimeric antigen receptors, designed to specifically identify and eliminate malignant cells. Its operations are divided into two distinct divisions: Therapeutics and Plants. The therapeutic pipeline includes several product candidates currently undergoing development. Among these is UCART19, an allogeneic T-cell therapy targeting CD19-expressing blood cancers such as acute lymphoblastic leukemia. Other key developments encompass ALLO-501 and ALLO-501A, designed for diffuse large B-cell lymphoma and follicular lymphoma in relapsed or refractory patients; ALLO-316, intended for Renal Cell Carcinoma; UCART123 for acute myeloid leukemia; and UCART22 for B-cell acute lymphoblastic leukemia. Furthermore, UCARTCS1 and ALLO-715 are being developed to combat multiple myeloma. Strategic partnerships form a crucial part of its operations, encompassing alliances with entities such as Allogene Therapeutics, Inc., Les Laboratoires Servier, The University of Texas M.D. Anderson Cancer Center, and Iovance Biotherapeutics. The firm also maintains a dedicated research and development collaboration with Cytovia Therapeutics, Inc. Established in 1999, Cellectis S.A. maintains its principal offices in Paris, France.

🦦